Review



acat1 inhibitor avasimibe  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress acat1 inhibitor avasimibe
    Acat1 Inhibitor Avasimibe, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acat1 inhibitor avasimibe/product/MedChemExpress
    Average 94 stars, based on 27 article reviews
    acat1 inhibitor avasimibe - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    acat1 inhibitor avasimibe  (MedChemExpress)
    94
    MedChemExpress acat1 inhibitor avasimibe
    Acat1 Inhibitor Avasimibe, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acat1 inhibitor avasimibe/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    acat1 inhibitor avasimibe - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    avasimibe-10 μm (acat1 and acat2 inhibitor)  (Cayman Chemical)
    90
    Cayman Chemical avasimibe-10 μm (acat1 and acat2 inhibitor)
    Yield of infectious HSV-1 and viral protein synthesis in BMDCs treated with inhibitors of lipid-metabolism-related enzymes Plaque-forming units (PFUs) and viral protein expression analyses (western blot) of HSV-1 late viral proteins (glycoprotein B, glycoprotein D, and VP16) in BMDCs treated for 3 h with the (A) DGAT1 inhibitor A-922500 (10 μM) (B) <t>DGAT2</t> inhibitor PF-06424439 (10 μM), (C) ACAT inhibitor avasimibe (10 μM), (D) ACS inhibitor TOFA (10 μM), (E) ACS inhibitor triacsin C (10 μM), (F) lipase inhibitor CAY10499 (10 μM), (G) FATP inhibitor lipofermata (10 μM), or (H) CD36 inhibitor sulfosuccinimidyl oleate (SSO, 50 μM) and then infected with HSV-1 strain F at MOI 3 for 12 hpi or 18 hpi. (−) corresponds to vehicle treatment (DMSO) and (+) to treatment with the inhibitor. C + corresponds to Vero-HSV-1-infected cells (positive control). The analyses shown are means ± SEM of three independent assays. The statistical analyses were performed using two-way ANOVA and Bonferroni multiple comparisons test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, ns: no statistical significance). See also <xref ref-type=Figure S5 . " width="250" height="auto" />
    Avasimibe 10 μm (Acat1 And Acat2 Inhibitor), supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/avasimibe-10 μm (acat1 and acat2 inhibitor)/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    avasimibe-10 μm (acat1 and acat2 inhibitor) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    acat1 inhibitors avasimibe  (MedChemExpress)
    94
    MedChemExpress acat1 inhibitors avasimibe
    Yield of infectious HSV-1 and viral protein synthesis in BMDCs treated with inhibitors of lipid-metabolism-related enzymes Plaque-forming units (PFUs) and viral protein expression analyses (western blot) of HSV-1 late viral proteins (glycoprotein B, glycoprotein D, and VP16) in BMDCs treated for 3 h with the (A) DGAT1 inhibitor A-922500 (10 μM) (B) <t>DGAT2</t> inhibitor PF-06424439 (10 μM), (C) ACAT inhibitor avasimibe (10 μM), (D) ACS inhibitor TOFA (10 μM), (E) ACS inhibitor triacsin C (10 μM), (F) lipase inhibitor CAY10499 (10 μM), (G) FATP inhibitor lipofermata (10 μM), or (H) CD36 inhibitor sulfosuccinimidyl oleate (SSO, 50 μM) and then infected with HSV-1 strain F at MOI 3 for 12 hpi or 18 hpi. (−) corresponds to vehicle treatment (DMSO) and (+) to treatment with the inhibitor. C + corresponds to Vero-HSV-1-infected cells (positive control). The analyses shown are means ± SEM of three independent assays. The statistical analyses were performed using two-way ANOVA and Bonferroni multiple comparisons test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, ns: no statistical significance). See also <xref ref-type=Figure S5 . " width="250" height="auto" />
    Acat1 Inhibitors Avasimibe, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acat1 inhibitors avasimibe/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    acat1 inhibitors avasimibe - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    acat1 inhibitor avasimibe  (Selleck Chemicals)
    94
    Selleck Chemicals acat1 inhibitor avasimibe
    Yield of infectious HSV-1 and viral protein synthesis in BMDCs treated with inhibitors of lipid-metabolism-related enzymes Plaque-forming units (PFUs) and viral protein expression analyses (western blot) of HSV-1 late viral proteins (glycoprotein B, glycoprotein D, and VP16) in BMDCs treated for 3 h with the (A) DGAT1 inhibitor A-922500 (10 μM) (B) <t>DGAT2</t> inhibitor PF-06424439 (10 μM), (C) ACAT inhibitor avasimibe (10 μM), (D) ACS inhibitor TOFA (10 μM), (E) ACS inhibitor triacsin C (10 μM), (F) lipase inhibitor CAY10499 (10 μM), (G) FATP inhibitor lipofermata (10 μM), or (H) CD36 inhibitor sulfosuccinimidyl oleate (SSO, 50 μM) and then infected with HSV-1 strain F at MOI 3 for 12 hpi or 18 hpi. (−) corresponds to vehicle treatment (DMSO) and (+) to treatment with the inhibitor. C + corresponds to Vero-HSV-1-infected cells (positive control). The analyses shown are means ± SEM of three independent assays. The statistical analyses were performed using two-way ANOVA and Bonferroni multiple comparisons test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, ns: no statistical significance). See also <xref ref-type=Figure S5 . " width="250" height="auto" />
    Acat1 Inhibitor Avasimibe, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acat1 inhibitor avasimibe/product/Selleck Chemicals
    Average 94 stars, based on 1 article reviews
    acat1 inhibitor avasimibe - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Yield of infectious HSV-1 and viral protein synthesis in BMDCs treated with inhibitors of lipid-metabolism-related enzymes Plaque-forming units (PFUs) and viral protein expression analyses (western blot) of HSV-1 late viral proteins (glycoprotein B, glycoprotein D, and VP16) in BMDCs treated for 3 h with the (A) DGAT1 inhibitor A-922500 (10 μM) (B) DGAT2 inhibitor PF-06424439 (10 μM), (C) ACAT inhibitor avasimibe (10 μM), (D) ACS inhibitor TOFA (10 μM), (E) ACS inhibitor triacsin C (10 μM), (F) lipase inhibitor CAY10499 (10 μM), (G) FATP inhibitor lipofermata (10 μM), or (H) CD36 inhibitor sulfosuccinimidyl oleate (SSO, 50 μM) and then infected with HSV-1 strain F at MOI 3 for 12 hpi or 18 hpi. (−) corresponds to vehicle treatment (DMSO) and (+) to treatment with the inhibitor. C + corresponds to Vero-HSV-1-infected cells (positive control). The analyses shown are means ± SEM of three independent assays. The statistical analyses were performed using two-way ANOVA and Bonferroni multiple comparisons test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, ns: no statistical significance). See also <xref ref-type=Figure S5 . " width="100%" height="100%">

    Journal: iScience

    Article Title: HSV-1 alters lipid metabolism and induces lipid droplet accumulation in functionally impaired mouse dendritic cells

    doi: 10.1016/j.isci.2025.112441

    Figure Lengend Snippet: Yield of infectious HSV-1 and viral protein synthesis in BMDCs treated with inhibitors of lipid-metabolism-related enzymes Plaque-forming units (PFUs) and viral protein expression analyses (western blot) of HSV-1 late viral proteins (glycoprotein B, glycoprotein D, and VP16) in BMDCs treated for 3 h with the (A) DGAT1 inhibitor A-922500 (10 μM) (B) DGAT2 inhibitor PF-06424439 (10 μM), (C) ACAT inhibitor avasimibe (10 μM), (D) ACS inhibitor TOFA (10 μM), (E) ACS inhibitor triacsin C (10 μM), (F) lipase inhibitor CAY10499 (10 μM), (G) FATP inhibitor lipofermata (10 μM), or (H) CD36 inhibitor sulfosuccinimidyl oleate (SSO, 50 μM) and then infected with HSV-1 strain F at MOI 3 for 12 hpi or 18 hpi. (−) corresponds to vehicle treatment (DMSO) and (+) to treatment with the inhibitor. C + corresponds to Vero-HSV-1-infected cells (positive control). The analyses shown are means ± SEM of three independent assays. The statistical analyses were performed using two-way ANOVA and Bonferroni multiple comparisons test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, ns: no statistical significance). See also Figure S5 .

    Article Snippet: The lipid metabolism inhibitors (all from Cayman chemical) were lipofermata-10 μM (FATP inhibitor), sulfosuccinimidyl oleate-50 μM (SSO-CD36 inhibitor), 5-(tetradecycloxy)-2-furancarboxylic acid (TOFA)-10 μM (ACC inhibitor), Triacsin C-10 μM (ACS inhibitor), A922500-10 μM (DGAT1 inhibitor), PF-06424439-10 μM (DGAT2 inhibitor), Avasimibe-10 μM (ACAT1 and ACAT2 inhibitor) and CAY10499-10 μM (Lipase inhibitor).

    Techniques: Expressing, Western Blot, Infection, Positive Control

    Inhibition of cholesterol ester synthesis (ACAT) or fatty acid uptake by fatty acid transport protein (FATP) recovers the viability of HSV-1-infected BMDCs Flow cytometry analyses of BMDC viability (determined as CD11c + /Zombie − cells) treated with (A) DGAT1 inhibitor A-922500 (10 μM), (B) DGAT2 inhibitor PF-06424439 (10 μM), (C) ACAT inhibitor avasimibe (10 μM), (D) ACS inhibitor TOFA (10 μM), (E) ACS inhibitor triacsin C (10 μM), (F) lipase inhibitor CAY10499 (10 μM), (G) FATP inhibitor lipofermata (10 μM), or (H) CD36 inhibitor sulfosuccinimidyl oleate (SSO, 50 μM) for 3 h, infected with HSV-1 strain F at MOI 3 for 1 h, and then further treated with the inhibitors for 17 h during infection. Vehicle treatment corresponds to the solvent used to dissolve the inhibitors (DMSO). The analyses shown are means ± SEM of three independent assays. The statistical analyses were performed using two-way ANOVA and Bonferroni multiple comparisons test (∗ p < 0.05, ∗∗ p < 0.01, ns: no statistical significance). See also <xref ref-type=Figures S6 and . " width="100%" height="100%">

    Journal: iScience

    Article Title: HSV-1 alters lipid metabolism and induces lipid droplet accumulation in functionally impaired mouse dendritic cells

    doi: 10.1016/j.isci.2025.112441

    Figure Lengend Snippet: Inhibition of cholesterol ester synthesis (ACAT) or fatty acid uptake by fatty acid transport protein (FATP) recovers the viability of HSV-1-infected BMDCs Flow cytometry analyses of BMDC viability (determined as CD11c + /Zombie − cells) treated with (A) DGAT1 inhibitor A-922500 (10 μM), (B) DGAT2 inhibitor PF-06424439 (10 μM), (C) ACAT inhibitor avasimibe (10 μM), (D) ACS inhibitor TOFA (10 μM), (E) ACS inhibitor triacsin C (10 μM), (F) lipase inhibitor CAY10499 (10 μM), (G) FATP inhibitor lipofermata (10 μM), or (H) CD36 inhibitor sulfosuccinimidyl oleate (SSO, 50 μM) for 3 h, infected with HSV-1 strain F at MOI 3 for 1 h, and then further treated with the inhibitors for 17 h during infection. Vehicle treatment corresponds to the solvent used to dissolve the inhibitors (DMSO). The analyses shown are means ± SEM of three independent assays. The statistical analyses were performed using two-way ANOVA and Bonferroni multiple comparisons test (∗ p < 0.05, ∗∗ p < 0.01, ns: no statistical significance). See also Figures S6 and .

    Article Snippet: The lipid metabolism inhibitors (all from Cayman chemical) were lipofermata-10 μM (FATP inhibitor), sulfosuccinimidyl oleate-50 μM (SSO-CD36 inhibitor), 5-(tetradecycloxy)-2-furancarboxylic acid (TOFA)-10 μM (ACC inhibitor), Triacsin C-10 μM (ACS inhibitor), A922500-10 μM (DGAT1 inhibitor), PF-06424439-10 μM (DGAT2 inhibitor), Avasimibe-10 μM (ACAT1 and ACAT2 inhibitor) and CAY10499-10 μM (Lipase inhibitor).

    Techniques: Inhibition, Infection, Flow Cytometry, Solvent